Skip to main content
CORT
NASDAQ Life Sciences

FDA Approves Corcept's Lifyorli for Platinum-Resistant Ovarian Cancer

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$41.08
Mkt Cap
$4.37B
52W Low
$28.66
52W High
$117.33
52W Position info
43% above low
Off High info
65% below high
Rel. Volume info
3.8× avg
Market data snapshot near publication time

CORT sits 43% above its 52-week low of $28.66 on elevated volume (3.8× avg).

Summary

Corcept Therapeutics announced FDA approval for Lifyorli (relacorilant) in combination with nab-paclitaxel for platinum-resistant ovarian cancer, marking a significant positive development and opening a new market.


Key Events · Product Development and Regulatory · CORT

  • FDA Approval Granted

    Lifyorli™ (relacorilant) has received U.S. Food and Drug Administration (FDA) approval in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

  • Strong Clinical Efficacy

    The approval is based on positive outcomes from the pivotal ROSELLA trial, which demonstrated a 35% reduction in the risk of death and a 30% reduction in the risk of disease progression for patients treated with Lifyorli plus nab-paclitaxel.

  • First-in-Class Drug

    Lifyorli is the first FDA-approved selective glucocorticoid receptor antagonist (SGRA), positioning it as a novel treatment option.

  • Significant Market Opportunity

    The treatment targets a substantial patient population, with approximately 20,000 women with platinum-resistant disease in the United States alone who are candidates for new therapy each year.


Analysis · CORT · Life Sciences

This 8-K announces a pivotal FDA approval for Lifyorli (relacorilant) in combination with nab-paclitaxel for platinum-resistant ovarian cancer. This is a significant positive development, especially given the company's prior setbacks, including a Complete Response Letter for relacorilant in a different indication and a decline in profitability. The approval, based on strong clinical data showing a 35% reduction in death risk and 30% reduction in disease progression, opens a substantial new market opportunity (estimated 20,000 patients annually in the US). As the first FDA-approved selective glucocorticoid receptor antagonist, Lifyorli could become a new standard of care, fundamentally improving Corcept's revenue outlook and investor sentiment.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 51.2% of the 201 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.73%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CORT was trading at $41.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $28.66 to $117.33. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CORT - Latest Insights

CORT
Nov 03, 2026, 4:11 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $78.50
Real-time Price: $72.77 info
Change: -$5.73 (-7%) info
Market Cap: $7.964B info
CORT
Nov 03, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $81.93
Real-time Price: $72.77 info
Change: -$9.16 (-11%) info
Market Cap: $7.964B info
CORT
Oct 26, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $86.01
Real-time Price: $72.77 info
Change: -$13.24 (-15%) info
Market Cap: $7.964B info
CORT
Oct 20, 2026, 4:00 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $116.51
Real-time Price: $72.77 info
Change: -$43.74 (-38%) info
Market Cap: $7.964B info
CORT
Sep 18, 2026, 8:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $114.90
Real-time Price: $72.77 info
Change: -$42.13 (-37%) info
Market Cap: $7.964B info